Key result
The fluoropolymer everolimus-eluting stent (FP-EES) demonstrated lower platelet adherence compared to BL-ZES, EP-RES, and bare metal stents.
Why the study?
The relative thrombogenicity and albumin adsorption and retention of different durable polymers used in coronary stents had not been tested.
Does the fluoropolymer everolimus-eluting stent improve thromboresistance and albumin retention compared to other durable polymer drug-eluting stents and bare metal stents in preclinical models?
Does the fluoropolymer everolimus-eluting stent improve thromboresistance and albumin retention compared to other durable polymer drug-eluting stents and bare metal stents in preclinical models?
Answers are grounded in this paper and cite their sources.
Fluoropolymer everolimus-eluting stents demonstrate superior thromboresistance and albumin retention compared to other durable polymer DES and bare metal stents in preclinical models, suggesting potential suitability for short-term dual antiplatelet therapy.
BACKGROUND: The relative thrombogenicity and albumin adsorption and retention of different durable polymers used in coronary stents has not been tested. AIMS: This study sought to compare the thromboresistance and albumin binding capacity of different durable polymer drug-eluting stents (DES) using dedicated preclinical and in vitro models. METHODS: In an ex vivo swine arteriovenous shunt model, a fluoropolymer everolimus-eluting stent (FP-EES) (n=14) was compared with two durable polymer DES, the BioLinx polymer-coated zotarolimus-eluting stent (BL-ZES) (n=9) and a CarboSil elastomer polymer-coated ridaforolimus-eluting stent (EP-RES) (n=6), and bare metal stents (BMS) (n=10). Stents underwent immunostaining using a cocktail of antiplatelet antibodies and a marker for inflammation and were then evaluated by confocal microscopy (CM). Albumin retention was assessed using a flow loop model with labelled human serum albumin (FP-EES [n=8], BL-ZES [n=4], EP-RES [n=4], and BMS [n=7]), and scanned by CM. RESULTS: The area of platelet adherence (normalised to total stent surface area) was lower in the order FP-EES (9.8%), BL-ZES (32.7%), EP-RES (87.6%) and BMS (202.0%), and inflammatory cell density was least for FP-EES <BL-ZES <EP-RES <BMS. Although nearly full coverage by albumin binding was shown for all durable polymer DES, FP-EES showed significantly greater intensity of albumin as compared to BL-ZES, EP-RES and BMS (FP-EES 79.0%; BL-ZES 13.2%; EP-RES 6.1%; BMS 1.5%). CONCLUSIONS: These results suggest that thromboresistance and albumin retention vary by polymer type and that these differences might result in different suitability for short-term dual antiplatelet therapy.
No takes yet. Share an insight, caveat, or question.
Jinnouchi et al. (2021) studied Preclinical stent evaluation (n=7). Fluoropolymer everolimus-eluting stent (FP-EES) vs. BioLinx polymer-coated zotarolimus-eluting stent (BL-ZES), CarboSil elastomer polymer-coated ridaforolimus-eluting stent (EP-RES), and bare metal stents (BMS) was evaluated on Area of platelet adherence (normalised to total stent surface area) (p=<0.01). The fluoropolymer everolimus-eluting stent (FP-EES) demonstrated lower platelet adherence compared to BL-ZES, EP-RES, and bare metal stents.
Synapse has enriched 10 related papers. Consider them for comparative context: